Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B/F/TAF to DTG/3TC Switch Study
PACTR202404870570433Phase 3Not yet recruiting
- Sponsor
- University of Nairobi
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of dolutegravir, lamivudine, bictegravir, emtricitabine and tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by University of Nairobi. Primary endpoint: Participants with plasma HIV-1 RNA greater than or equal to 50 copies/mL at Week 48. Planned start May 2024; status: not yet recruiting.
02
Drugs
dolutegravirlamivudinebictegraviremtricitabinetenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202404870570433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202404870570433.